Aim. The aim of this study was to compare the effect of pentoxifylline versus placebo on serum concentrations of tumor necrosis factor-alpha (TNF-a), interleukin 6 (IL-6) and C-reactive protein (CRP) of hemodialysis (HD) patients. Methods. This is a randomized double-blind, controlled clinical trial. HD patients without infection or drugs with anti-inflammatory effect were randomly allocated to a study (n ¼ 18, pentoxifylline 400 mg/day) or control (n ¼ 18, placebo) group; all patients had arteriovenous fistula. Besides clinical and laboratory monthly assessments, serum TNF-a and IL-6 (ELISA) and CRP (nephelometry) were measured at 0, 2 and 4 months. Conclusions. Pentoxifylline significantly decreased serum concentrations of TNF-a, IL-6 and CRP compared to placebo. Pentoxifylline could be a promising and useful strategy to reduce the systemic inflammation frequently observed in patients on HD.
Introduction
Chronic inflammation is strongly linked to atherosclerosis, cardiovascular disease and malnutrition in patients with end-stage renal disease (ESRD) [1] [2] [3] . Moreover, mortality in this kind of patients is almost nine times higher than for the general population and largely caused by atherosclerotic cardiovascular disease [2] [3] [4] .
Etiology of inflammation in renal disease is multiple and includes uremia per se, comorbidities, renal replacement therapy and hidden infections, among others [5] . Patients on hemodialysis (HD) display the highest level of inflammation, probably due to exposure to endotoxin and other pollutants, bioincompatible dialysis solution and dialysis membrane [5, 6] .
Therapeutic interventions targeting chronic inflammation in HD patients may lead to improved outcomes. Some therapeutic agents are being studied in early clinical trials, while others could become viable alternatives in the future [7] . Pentoxifylline, a non-selective phosphodiesterase inhibitor could be an effective alternative in patients with kidney failure. This drug has been extensively studied in animal models and humans without kidney disease, and its antithrombotic and hemorrheologic properties are well established [8] . In addition, pentoxifylline has been shown in vitro and in vivo to downregulate the expression of tumor necrosis factor alpha (TNFa), interleukin (IL)-1b, IL-6 and IL-8 [9, 10] . Pentoxifylline also increases anti-inflammatory IL-10 [11, 12] . However, there is little data about the anti-inflammatory effect of pentoxifylline in patients with kidney disease, and particularly, no randomized clinical trial has evaluated this drug in HD.
Size and duration of clinical end-point trials required to establish benefit of treatment regimens have become daunting; instead, some biomarkers are used as potential surrogates of cardiovascular risk [13] . Therefore, this study was designed to compare the effect of pentoxifylline versus placebo on serum concentrations of TNF-a, IL-6 and Creactive protein (CRP) in patients on HD.
Materials and methods
This was a randomized double-blind, placebo-controlled clinical trial, performed in a tertiary-care teaching hospital (Hospital de Especialidades, CMNO, IMSS) in Guadalajara, Mexico, from January 2006 to May 2008.
A flow diagram summarizing recruitment and follow-up of patients is shown in Figure 1 . From the total 105 patients attending the HD unit of our hospital, 36 were selected by simple random sampling. If patients met the selection criteria, they were invited to participate in the study. Inclusion criteria were age !18 years, !2 months on HD, arteriovenous fistula as vascular access and endorsement of informed consent. Patients were excluded if they had inflammatory cause of ESRD, liver disease, cancer, AIDS, any infectious disease 2 months before the study, failed kidney graft, hypersensitivity to pentoxifylline or other methylxanthines, hemorrhage/clotting disorders, risk for worsening pre-existing cardiac arrhythmias or arterial hypotension or treatment with antibiotics, non-steroidal anti-inflammatory drugs, steroids, immunosuppressives, statins or pentoxifylline 3 months previous to the study.
Once included (after a written consent was obtained), patients were randomly allocated (by a computer-generated randomization list) to a study or control group. Over a period of 4 months, patients of the study group received one pentoxifylline tablet (400 mg) orally once a day (at dinner time), whereas controls received one identical starch tablet on the same schedule. Pentoxifylline dose was selected based on previous pharmacological and clinical studies about the use of this drug in patients with renal impairment [14, 15] .
All patients had three HD sessions per week, with the same kind of single-use dialysis membrane (cellulose triacetate; Nipro Corporation, Osaka, Japan) and dialyzate (bicarbonate 35 mEq/L, calcium 2.5 mEq/L, potassium 2 mEq/L). Ultrafiltered dialyzate was checked by triplicate every month, using agar plates at 37°C for at least 3 days; results were 0.1 CFU/mL throughout the study.
Monthly visits were scheduled for clinical and biochemical evaluations. Once any current infection was excluded, a blood sample was taken at baseline and every month for measurement of complete blood count, urea, creatinine, glucose, albumin, lipids and electrolytes (measured by usual methods). In serum samples at 0, 2 and 4 months, TNF-a and IL-6 concentrations were measured by ELISA, using high-sensitivity kits (Amersham Pharmacia Biotech, Buckinghamshire, UK). Additionally, in the same serum samples, CRP concentrations were measured by nephelometry, using highsensitivity kits (Dade Behring, Marburg, Germany) in a Nephelometry Analyzer II (Dade Behring). Lower detection limit was 0.3 pg/mL for TNF-a, 0.1 pg/mL for IL-6 and 0.1 mg/L for CRP; when a result was lower than those limits, it was considered as zero. In previous studies, [16] inter-and intraassay variations were 3.4 and 3.4% for CRP, 3.9 and 4.6% for IL-6 and 2.8 and 6% for TNF-a, respectively. Dialysis dose was measured as equilibrated Kt/V urea [17] at 0 and 4 months. All laboratory measurements, including inflammation markers, were performed by the same personnel in the Central Laboratory (Hospital de Especialidades, CMNO). All patients, personnel and investigators, including the persons responsible for data management and statistics, were blinded to the treatment assignment. The code was opened only after recruitment and data collection of all patients had been completed.
Treatment compliance was recorded by counting tablets left in the container at the end of each monthly visit.
The study was approved by the Institutional Review Board (Hospital de Especialidades, CMNO, No. R-2006-1301-38) and registered in the US National Institutes of Health (NCT01269827).
Statiscal analysis
An a priori sample size was calculated considering a reduction of 50% on CRP levels currently found in our setting (5.7 AE 1.9 mg/L; À ngel-Zúñiga JR, Rojas Campos E, Martín-del-Campo F, Camacho R, Nava D and Cueto-Manzano AM, unpublished data) as well as the effect of pentoxifylline on TNF-a previously reported in non-dialysis patients [15] . Using a formula for testing proportion differences in clinical trials [18] 
Results
In general, intermediate evaluations (1, 2 and 3 months) were in agreement with final results (4 months); however, to simplify data presentation, only baseline and final results are shown. Adherence to treatment was 99% in both groups during the whole study.
From the 18 patients in control group, 1 patient received a kidney transplant and was removed from the study but not from the analysis.
There were no significant differences between groups regarding demographic and clinical variables at baseline (Table 1) . Table 2 shows comparisons of clinical-and dialysis-related variables between groups at the beginning and the end of the study. Equilibrated Kt/V urea was higher in the control group since the beginning of the study; however, all its measurements were within recommended values in both groups. No other difference in these variables was observed between groups.
Results of biochemical variables are shown in Table 3 . Serum albumin and phosphorus were significantly lower in controls at the end of the follow-up compared to patients in the study group. Although non-significant, patients of the study group tended to decrease serum triglycerides at final evaluation, contrary to the observed in controls. No other biochemical variable displayed significant differences neither for inter-nor intra-group comparisons. Figure 2 displays results of the inflammation markers in both groups. Median serum concentrations of TNF-a, IL-6 and CRP significantly decreased in the study group at the end of the follow-up, whereas they remained roughly the same or increased in the control group.
Comparisons of the inflammation markers

patients randomly allocated:
18 in pentoxifylline group received 18 in placebo group received intervention 18 patients followed-up at the end 17 patients followed-up at the end 1 patient eliminated (received a kidney transplant)
18 patients analyzed 18 patients analyzed No serious adverse event was observed in any of the groups throughout the study.
Discussion
This is the first randomized double-blind, controlled clinical trial of the effect of pentoxifylline on systemic inflammation of HD patients. Results showed that pentoxifylline decreases the inflammatory cascade, as measured by the serum levels of TNF-a, IL-6 and CRP, compared to placebo.
Pentoxifylline inhibits phosphodiesterase, resulting in an increase of intracellular cyclic adenosine monophosphate activity and down-regulation of pro-inflammatory cytokine synthesis such as TNF-a, IL-6 and interferon-c [9, 10] ; this drug also inhibits proliferation of peripheral blood mononuclear cell, adherence to the cell matrix and endothelium and T and natural killer cell cytotoxicity [12, 19] . Pentoxifylline inhibits synthesis of the inflammation markers at a transcriptional level [9, 10] , which may represent an advantage over other anti-cytokine drugs, for example etanercept, which only stabilizes TNF-a and hence leads to accumulation in peripheral circulation [20] .
In association with their anti-inflammatory effects, pentoxifylline may reduce mortality and/or morbidity in pre-term neonates with sepsis, necrotizing enterocolitis and chronic lung disease [10, 21] , achieve some successes in alcoholic liver disease [22] , reduce acute side effects and late sequelae of radiation oncology [23] and have beneficial effects on multiple surrogate inflammation and clinical markers of chronic heart failure [19, 20] . On the other hand, few studies have been published in patients with kidney disease, and unfortunately, not many of high quality [24] . In uremic rats, pentoxifylline treatment prevented the increase in serum concentrations of inflammation and oxidative stress markers induced by high sodium intake [25] . In humans, this drug was effective in reducing proteinuria of diabetic patients with Pentoxifylline decreases inflammatory markers in hemodialysis advanced renal failure, which was strongly correlated with reduction in serum concentrations of TNF-a [15] . In a small case series study [26] , eight patients on HD and four on peritoneal dialysis with recombinant human erythropoietinresistant anemia were treated with pentoxifylline; after 4 months, this drug significantly improved the hemoglobin response coincidentally with inhibition of TNF-a and interferon gamma production. In our patients, hemoglobin levels were not different between groups; this issue, however, cannot be appropriately evaluated in the present study as erythropoietin dose was not controlled by researchers, and its use is still a matter with local economical implications. Two other findings that may add support to the anti-inflammatory effect of pentoxifylline are the better preservation of serum albumin and the trend to decrease serum triglycerides in the study group compared to controls [27] .
On the other hand, most of the patients included in both groups had an unknown cause of ESRD, which is a common finding in our setting [16, 28] ; however, none of them had a suspected inflammatory etiology. Variables related to HD procedure that could potentially affect inflammation results [29] [30] [31] were controlled in the current study, as all patients were treated with the same dialysis solution, vascular access and length of HD session. Although to a significantly lesser extent compared with bioincompatible membranes, cellulose triacetate membranes may still activate complement and cause cytokine production, neutropenia, fagocytotic and oxygen species production alterations [29] . This methodological problem was sorted out in our study as patients in both groups were treated with the same kind of hemodialyzers. Lower dose of dialysis may be associated with higher inflammation [31] ; however, this was not the case in the present study as patients treated with pentoxifylline received lower dose of dialysis (within recommended levels [32] ) and had the lower levels of inflammatory markers at the end of the follow-up. Overhydration, implicated in the genesis of inflammation [31] was also controlled as patients in both groups had similar ultrafiltration rates and post-dialysis weight throughout the study. Moreover, several comorbid conditions (arterial hypertension, obesity, and diabetes mellitus), also implicated in inflammation [33] [34] [35] , were not significantly different between groups.
Treatment compliance of 99% in both groups and similar conditions for measurement of inflammatory markers strengthen our results. However, the presence of hidden infections (Chlamydia pneumoniae, Helicobacter pylorii, chronic periodontal disease) as cause of inflammation [36] may be regarded as a possible limitation. Although the latter infections were not investigated with a more in-depth laboratory evaluation, they were clinically discarded with a meticulous physical examination and clinical chart revision; randomization could have also helped to solve this problem. Sample size could be considered too small to find differences between groups; however, it was calculated a priori (80% confidence level, alpha 0.05) to find a 50% reduction in CRP and TNF-a serum concentrations. Further studies with larger numbers of patients will help to support our findings. Follow-up may seem to be short; however, according to the pharmacology of pentoxifylline and results from previous studies, 4 months seem to be enough time to observe an effect on inflammation markers.
Conclusions
Pentoxifylline progressively and significantly reduced serum levels of TNF-a, IL-6 and CRP compared to placebo. This drug could be a promising and useful strategy to reduce the systemic inflammation frequently observed in patients with ESRD on HD, which may potentially have an effect on cardiovascular complications, but that needs to be investigated separately.
